MAY 11, 2017 06:20 AM PDT

First ALS Drug Approved in Over 2 Decades

WRITTEN BY: Xuan Pham

For the first time in over 20 years, the US Food and Drug Administration approved a new drug for the treatment of a disease commonly known as Lou Gehrig’s disease.

Known formally as amyotrophic lateral sclerosis (ALS), Lou Gehrig's disease is a fatal condition caused by the gradual breakdown and death of motor neurons in the spinal cord. All muscles under voluntary control are affected, causing muscle weakness and severe impairments in daily functions. There is no known cure and most ALS patients die from respiratory failure within 3 to 5 years from the onset of symptoms.

The new drug is known as Radicava or edaravone, and it was developed by Japanese Mitsubishi Tanabe Pharma. Trials for the drug conducted in Japan showed the drug slowed the progression of the disease. The 2015 phase 3 data from a six-month placebo-controlled study found the drug contributed to a 33 percent reduction in physical decline in ALS patients. So while the drug can’t reverse the trajectory of ALS, it could give patients just a little more time and freedom.

Interestingly, the FDA’s approval of the drug was based solely on data collected from the Japanese trial. These results were so compelling that the FDA worked with the company to file for US approval.

“After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States,” said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option.”

Radicava is administered intravenously, with each infusion estimated to cost $1,086, and a year’s treatment costing $145,524 without assistance.

Prior to radicava, the 12-15,000 ALS patients had access to only one other approved ALS drug, riluzole by Sanofi. Riluzole was approved for ALS in 1995. Similar to radicava, the drug slows the progression of the disease, delaying the onset of ventilator-dependence and tracheotomy in some patients. The drug is estimated to prolong survival by two to three months.

For ALS patients and advocates, the approval of radicava marks a significant milestone. "We thank the FDA and MT Pharma for working together to expedite the approval of the first new ALS-specific treatment in decades," said ALS Association President Barbara Newhouse. "We hope (the) announcement signals the beginning of a new chapter in the fight against this terrible disease." The new drug is expected to come on the US market in August 2017.

Additional source: CNN

Image credit: pixabay.com

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 27, 2018
Clinical & Molecular DX
APR 27, 2018
Stomach Pain Is A Warning Sign for Meningitis
Simply looking out for the classic warning signs of a meningococcal infection may cause some cases to go unnoticed - at first. A new study from the Institu...
MAY 21, 2018
Genetics & Genomics
MAY 21, 2018
Using CRISPR for High-throughout Genetic Assessment
Researchers can now move beyond the painstaking manipulation of individual genes....
JUN 16, 2018
Clinical & Molecular DX
JUN 16, 2018
Nanoparticles Deliver "Theranostics" for Cancer Patients
New technology combing therapeutic agents and diagnostics (theranostics) can be used to deliver drugs to cancer cells. From the Moscow Institute of Physics...
JUN 20, 2018
Genetics & Genomics
JUN 20, 2018
The Cause of a Rare Neurological Disease is Identified
In a recent study, scientists sequenced the genome to find the mutation behind a disorder that causes blindness and paralysis....
AUG 08, 2018
Microbiology
AUG 08, 2018
Use of Probiotics Linked to Severe Bloating, Brain Fog
Gut bacteria can have a powerful effect on brain function....
AUG 30, 2018
Genetics & Genomics
AUG 30, 2018
Genetic Changes can Help Diagnose Childhood Cancers Far Earlier
New research has revealed genetic rearrangements that happen far before bone cancer starts growing in children....
Loading Comments...